Perbak Capital Partners LLP Has $4.68 Million Position in Qiagen N.V. $QGEN

Perbak Capital Partners LLP boosted its stake in shares of Qiagen N.V. (NYSE:QGEN) by 78.2% during the third quarter, HoldingsChannel.com reports. The firm owned 104,838 shares of the company’s stock after acquiring an additional 46,002 shares during the period. Qiagen makes up about 0.8% of Perbak Capital Partners LLP’s portfolio, making the stock its 13th largest holding. Perbak Capital Partners LLP’s holdings in Qiagen were worth $4,684,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in QGEN. Boston Partners purchased a new stake in Qiagen in the 3rd quarter worth approximately $179,450,000. Norges Bank purchased a new position in shares of Qiagen during the 2nd quarter valued at $158,728,000. Dimensional Fund Advisors LP purchased a new position in shares of Qiagen during the 3rd quarter valued at $58,079,000. JPMorgan Chase & Co. increased its stake in shares of Qiagen by 117.0% in the second quarter. JPMorgan Chase & Co. now owns 1,252,948 shares of the company’s stock worth $60,217,000 after acquiring an additional 675,498 shares during the last quarter. Finally, Invesco Ltd. increased its stake in shares of Qiagen by 123.7% in the second quarter. Invesco Ltd. now owns 1,006,025 shares of the company’s stock worth $48,350,000 after acquiring an additional 556,387 shares during the last quarter. Hedge funds and other institutional investors own 70.00% of the company’s stock.

Qiagen Stock Performance

NYSE QGEN opened at $40.59 on Friday. The company has a debt-to-equity ratio of 0.44, a current ratio of 3.90 and a quick ratio of 3.31. The firm has a market capitalization of $8.57 billion, a price-to-earnings ratio of 20.13, a P/E/G ratio of 2.01 and a beta of 0.70. The company’s fifty day moving average is $49.32 and its two-hundred day moving average is $48.86. Qiagen N.V. has a 52-week low of $40.14 and a 52-week high of $57.81.

Qiagen (NYSE:QGEN) last announced its quarterly earnings data on Thursday, February 5th. The company reported $0.62 EPS for the quarter, beating analysts’ consensus estimates of $0.61 by $0.01. Qiagen had a net margin of 20.33% and a return on equity of 14.56%. The business had revenue of $540.42 million during the quarter, compared to analyst estimates of $528.53 million. During the same quarter in the prior year, the business earned $0.61 earnings per share. The firm’s revenue for the quarter was up 3.6% on a year-over-year basis. Equities research analysts forecast that Qiagen N.V. will post 2.26 EPS for the current year.

Analyst Ratings Changes

QGEN has been the subject of a number of research reports. TD Cowen reissued a “hold” rating on shares of Qiagen in a research report on Friday, February 6th. Zacks Research lowered Qiagen from a “hold” rating to a “strong sell” rating in a research report on Monday, March 9th. Deutsche Bank Aktiengesellschaft raised Qiagen from a “hold” rating to a “buy” rating and set a $54.00 price target for the company in a research note on Friday. Barclays set a $58.00 price target on Qiagen and gave the company an “overweight” rating in a report on Friday, February 6th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Qiagen in a report on Monday, December 29th. Five equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $55.20.

Qiagen Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.